Comparative Analysis of Low-Dose Oral Minoxidil with Spironolactone Versus Finasteride or Dutasteride in Female Androgenetic Alopecia Management

September 2024 in “ Archives of Dermatological Research ”

Deesha Desai, Ambika Nohria, Michelle Sikora, Nnaemeka Anyanwu, Jerry Shapiro, Kristen I. Lo Sicco

low-dose oral minoxidil spironolactone finasteride dutasteride female androgenetic alopecia hair growth hair density LDOM Propecia AGA

From the encyclopedia

Spironolactone →

powerful topical and oral anti-androgen used mostly by women

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Studysummary Both treatment combinations improved hair growth similarly and were safe. Our plain-language summary of this paper — not a Tressless recommendation.

This study compared the efficacy and safety of low-dose oral minoxidil (LDOM) combined with either spironolactone or finasteride/dutasteride in treating female androgenetic alopecia (AGA). Both combination therapies showed similar improvements in hair growth and had comparable safety profiles. Although the group using LDOM with finasteride/dutasteride experienced a greater average increase in hair width and density, these differences were not statistically significant. The findings support the use of LDOM with either spironolactone or finasteride/dutasteride for female AGA and highlight the need for further research to confirm these results and evaluate long-term outcomes.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Safety of Low-Dose Oral Minoxidil for Hair Loss: A Multicenter Study of 1404 Patients

39 citations , February 2021 in “Journal of The American Academy of Dermatology”

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

A Randomized, Double-Blind Controlled Study of the Efficacy and Safety of Topical Solution of 0.25% Finasteride Admixed with 3% Minoxidil vs. 3% Minoxidil Solution in the Treatment of Male Androgenetic Alopecia

research A Randomized, Double-Blind Controlled Study of the Efficacy and Safety of Topical Solution of 0.25% Finasteride Admixed with 3% Minoxidil vs. 3% Minoxidil Solution in the Treatment of Male Androgenetic Alopecia

43 citations , July 2018 in “Journal of The European Academy of Dermatology and Venereology”

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

research Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss

53 citations , May 2010 in “PubMed”

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

research Treatment of Female Pattern Hair Loss With Oral Antiandrogens

179 citations , March 2005 in “British Journal of Dermatology”

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.